Finch and Takeda Expand Their Collaboration to Target Crohn’s Treatment Development

Finch and Takeda Expand Their Collaboration to Target Crohn’s Treatment Development
Finch Therapeutics and Takeda Pharmaceutical are joining forces to develop a treatment for Crohn’s disease — expanding their partnership in their development program for inflammatory bowel disease (IBD), which includes an ulcerative colitis treatment candidate. The expanded agreement calls for microbiome-based treatment development using Finch’s Human-First Discovery platform, and for Takeda to get exclusive worldwide rights to commercialize a Rationally Selected Microbiota (RSM) product developed for Crohn’s. Financial terms were not disclosed. In collaboration with Takeda, Finch’s first RSM product — FIN-524 — is in preclinical development for ulcerative colitis (UC). The RSM platform uses machine-learning algorithms to mine Finch’s unique clinical datasets to identify the key microbes driving patient outcomes. “We are pleased to expand our collaboration with Takeda,” Mark Smith, PhD, Finch CEO, said in a press release. “We’ve had a very fruitful collaboration with Takeda on the development of FIN-524, and we look forward to utilizing the knowledge we’ve built together to pursue the development of new therapeutic options for an even wider group of patients battling IBD.” Built on 30 years of translational research, Finch’s Human-First Discovery platform develops therapies from microbes that have shown significant clinical impact. In addition to RSM — a product platform based on microbes grown in cultures — it also has a donor-derived Full-Spectrum Microbiota product platform, which restores the functional diversity lost after disruptions to the microbiome. Finch is using the Human-First Discovery platform for a range of diseases linked to dysbiosis (imbalance) of the gut microbiome, the community of bacteria and micro
Subscribe or to access all post and page content.